Sidley represented MiMedx Group, Inc. in connection with its concurrent US$150 million equity and debt financing with EW Healthcare Partners and Hayfin Capital Management LLP. MiMedx is a biopharmaceutical company developing, manufacturing, and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare.
The deal was led by partners Asi Kirmayer (M&A), Beth Berg (M&A), and Ram Burshtine (Global Finance) with overall coordination by partner Isaac Greaney (Litigation) and included partners Daniel Altman (Tax), Laura Barzilai (Tax), Craig Dukin (White Collar: Government Litigation and Investigations), Sean Griffin (Food, Drug, and Medical Device Regulatory), Kate Heinzelman (Privacy and Cybersecurity), Joshua Hofheimer (Technology and IP Transactions), Donielle McCutcheon (Healthcare), Leslie Shubert (White Collar: Government Litigation and Investigations), Scott Stein (Healthcare); counsel Dusan Clark (Technology and IP Transactions), Maureen Crough (Environmental), Robert Hardy (Employee Benefits), Eric Hoffman (Labor, Employment, and Immigration); and associates Summer Danzeisen (Technology and IP Transactions), Jason Marsico (Labor, Employment, and Immigration), Martin Michalski (Global Finance), Philipp Nuernberger (M&A), Daniel Pruze (M&A), Lena Qiu (Tax), Michael Roberts (Privacy and Cybersecurity), Melissa Wu (Healthcare), Ben Yang (Global Finance), and David Zhao (M&A).